Duopharma Biotech Bhd
🇲🇾XKLS.7148MalaysiaHealthcare
PriceMYRÂ 1.19+0.03 (+2.59%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 0
- Medium: 0
- Low: 0
52-week low: the price is trading close to this level
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Malaysia
Identity
- Exchange
- Bursa Malaysia . XKLS
- Type
- Stock
- ISIN
- MYL7148OO009
- CUSIP
- Not reported
Company
- Employees
- 1,957
- Headquarters
- Klang, Malaysia
- Website
- https://duopharmabiotech.com
Market
- Shares outstanding
- 961.9M
- Market cap
- MYRÂ 1.14B
Highlights
- Market cap
- MYRÂ 1.14B
- EPS LTM
- MYRÂ 0.08
- P/E LTM
- 14.96calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 0.17%calculatedCalculated by Finzer, not reported by the data provider.
Fundamentals (LTM)
- Revenue
- MYRÂ 886.92M+18.57%up year on year
- Net income
- MYRÂ 76.52M+54.78%up year on year
- Gross margin
- 37.06%+3%up year on year
- Free cash flow
- MYRÂ 89.61M+264.04%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Duopharma Biotech Bhd is a company in the healthcare sector, listed on Bursa Malaysia (Malaysia) under the ticker 7148. Its market capitalisation is MYRÂ 1.14B, from 961.9M shares outstanding, as of . Across the 246 trading sessions to the shares traded between MYRÂ 1.15 and MYRÂ 1.57, and the last close of MYRÂ 1.19 sits 10% of the way up that range. The company is headquartered in Klang, Malaysia, and employs about 1,957 people.
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, including diabetes, cancer, cardiovascular, renal, and other diseases. The company's product portfolio includes covasc, crystorvas, and vytocor; lebreta, and krabeva; and unihepa, erysaa, bi-haemosol, and haemosol. In addition, it offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, IRORO Nutreatment, and Uphamol brands. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is based in Klang, Malaysia.